{
    "body": "Is dexamethasone recommended for treatment of intracerebral hemorrhage?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19108704", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16034939", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3574383"
    ], 
    "triples": [
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0011777", 
            "o": "dexamethasone"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0011777", 
            "o": "http://linkedlifedata.com/resource/umls/label/A0477612"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A0477612", 
            "o": "dexamethasone"
        }
    ], 
    "ideal_answer": [
        "No. Dexamethasone and other glucocorticoids should be avoided for treatment of intracerebral hemorrhage because they do not improve patient outcome and are associated with increased risk of side effects."
    ], 
    "exact_answer": "no", 
    "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002543", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045506", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4271528", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020299", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003907", 
        "http://www.biosemantics.org/jochem#4271528"
    ], 
    "type": "yesno", 
    "id": "58ec5ffaeda5a5767200000a", 
    "snippets": [
        {
            "offsetInBeginSection": 625, 
            "offsetInEndSection": 684, 
            "text": "Dexamethasone and other glucocorticoids should be avoided. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19108704", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 582, 
            "offsetInEndSection": 1206, 
            "text": "During the third interim analysis, the death rate at the 21st day was identical in the two groups (dexamethasone vs. placebo, 21 of 46 vs. 21 of 47; chi-square = 0.01, P = 0.93). In contrast, the rate of complications (mostly infections and complications of diabetes) was much higher in the dexamethasone group (chi-square = 10.89, P less than 0.001), leading to early termination of the study. In the light of the absence of a demonstrable beneficial effect and the presence of a significant harmful effect, current practices of using dexamethasone for treatment of primary supratentorial hemorrhage should be reconsidered.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/3574383", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 977, 
            "offsetInEndSection": 1206, 
            "text": "In the light of the absence of a demonstrable beneficial effect and the presence of a significant harmful effect, current practices of using dexamethasone for treatment of primary supratentorial hemorrhage should be reconsidered.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/3574383", 
            "endSection": "abstract"
        }
    ]
}